



Public Announcement
FOR IMMEDIATE RELEASE

**Puresyn and MavriX Bio Announce Manufacturing Partnership to Advance
Therapies for Angelman Syndrome**

MALVERN, PA September 15, 2026 – Puresyn, a specialized provider of plasmid DNA development and manufacturing services, and MavriX Bio, a clinical-stage biotechnology company focused on developing transformative genetic therapies for Angelman syndrome, today announced a manufacturing agreement to support the continued advancement of MavriX Bio's investigational gene replacement therapy, MVX-220.

The manufacturing agreement brings together Puresyn's capabilities in high-quality plasmid DNA development and manufacturing with MavriX Bio's focus on the development of genetic medicines to address unmet medical needs for individuals living with Angelman syndrome.

"We are pleased to partner with MavriX in support of their efforts to advance a potential treatment for Angelman syndrome," said Michael Moxley, Director of Business and Process Development at Puresyn. "Our experience in plasmid DNA manufacturing and quality systems allows us to provide a strong manufacturing foundation as MavriX continues to support its program through ongoing clinical development, and we are proud to play a role in helping bring new options to patients with serious and rare diseases."

Under the terms of the agreement, Puresyn will provide plasmid DNA development and manufacturing services to support MavriX Bio's ongoing clinical manufacturing activities. The organizations will work closely to support plasmid manufacturing processes, address evolving program requirements, and provide reliable, cost-efficient production to support clinical development needs.

The collaboration reflects a shared commitment to addressing the unique challenges of rare disease drug development. By leveraging complementary expertise, Puresyn and MavriX Bio intend to streamline plasmid manufacturing workflows, support manufacturing continuity, and establish a scalable foundation capable of supporting the program through key clinical milestones.

About Puresyn

Puresyn is a contract development and manufacturing organization specializing in plasmid DNA services, offering research-grade, INDReady®, and cGMP plasmid production supported by established quality systems and scalable manufacturing infrastructure. Puresyn supports biopharmaceutical and cell and gene therapy companies from early discovery through commercial development with a focus on reliability, technical excellence, and responsive collaboration.

About Mavrix Bio

MavriX Bio is a clinical-stage biotechnology company developing genetic medicines for severe neurological disorders with high unmet need. The company advances programs from discovery through early clinical development and collaborates with academic centers, investigators, and patient organizations to accelerate responsible innovation. For more information, visit mvxbio.com..

Media Contact:

Puresyn:

Michael Moxley

Director, Business and Process Development

mmoxley@puresyn.com